Prophylactic Treatment of Migraine With an Angiotensin II ReceptorBlocker
Top Cited Papers
Open Access
- 1 January 2003
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 289 (1) , 65-69
- https://doi.org/10.1001/jama.289.1.65
Abstract
Worldwide, approximately 240 million people have an estimated 1.4 billion attacks of migraine each year.1 The effect of this illness on society has been characterized by the World Health Organization using the Global Burden of Disease scale,2 which includes severe migraine in the highest disability class (together with active psychosis, dementia, and quadriplegia), emphasizing that this illness represents a serious health problem both for individuals and for society.Keywords
This publication has 20 references indexed in Scilit:
- Angiotensin II Increases Parathyroid Hormone-Related Protein (PTHrP) and the Type 1 PTH/PTHrP Receptor in the KidneyJournal of the American Society of Nephrology, 2002
- Efficacy and Tolerability in Migraine Prophylaxis of Flunarizine in Reduced Doses: A Comparison with Propranolol 160 Mg DailyCephalalgia, 2002
- Locally synthesized angiotensin modulates pineal melatonin generationJournal of Neurochemistry, 2002
- The prevention of migraine: a critical review with special emphasis on β‐adrenoceptor blockersBritish Journal of Clinical Pharmacology, 2001
- Guidelines for Controlled Trials of Drugs in Migraine: Second EditionCephalalgia, 2000
- Angiotensin II AT 1 Blockade Normalizes Cerebrovascular Autoregulation and Reduces Cerebral Ischemia in Spontaneously Hypertensive RatsStroke, 2000
- Angiotensin receptors in the nervous systemBrain Research Bulletin, 1998
- Pathophysiology and clinical presentations of cough☆☆☆★Journal of Allergy and Clinical Immunology, 1996
- Angiooedema and urticaria with angiotensin converting enzyme inhibitorsEuropean Journal of Clinical Pharmacology, 1996
- Sodium Valproate in The Prophylactic Treatment of Migraine: A Double-Blind Study Versus PlaceboCephalalgia, 1992